Generic name: SELEXIPAG 200ug
Dosage form: tablet, coated
The recommended starting dose of UPTRAVI is 200 micrograms (mcg) given twice daily. Tolerability may be improved when taken with food [see Clinical Pharmacology (12.3)].
Increase the dose in increments of 200 mcg twice daily, usually at weekly intervals, to the highest tolerated dose up to 1600 mcg twice daily. If a patient reaches a dose that cannot be tolerated, the dose should be reduced to the previous tolerated dose.
Do not split, crush, or chew tablets.
Interruptions and Discontinuations
If a dose of medication is missed, patients should take a missed dose as soon as possible unless the next dose is within the next 6 hours.
If treatment is missed for 3 days or more, restart UPTRAVI at a lower dose and then retitrate.
Dosage Adjustment in Patients with Hepatic Impairment
No dose adjustment of UPTRAVI is necessary for patients with mild hepatic impairment (Child-Pugh class A).
For patients with moderate hepatic impairment (Child-Pugh class B), the starting dose of UPTRAVI is 200 mcg once daily. Increase in increments of 200 mcg once daily at weekly intervals, as tolerated [see Use in Specific Populations (8.6), and Clinical Pharmacology (12.3)].
Avoid use of UPTRAVI in patients with severe hepatic impairment (Child-Pugh class C).
More about Uptravi (selexipag)
- Side Effects
- During Pregnancy
- Dosage Information
- Drug Images
- Drug Interactions
- Support Group
- Pricing & Coupons
- En Español
- 4 Reviews – Add your own review/rating
- Drug class: agents for pulmonary hypertension